Long-Term Contingent Consideration Payable (Tables)

12 Months Ended

Dec. 31, 2015

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Long-term contingent consideration payable and related activity are reported at fair value and consist of the following at December 31, 2015 and 2014:

			Activity During Year Ended December 31, 2015
					Changes in Fair Value of
					Contingent Consideration
					Operating		Interest
	Balance,		Payments to		Expense;		Expense;		Balance,
	December		Related		Acquisition-		Financing-		December 31,
	31, 2014		Parties		Related		Related		2015

Acquisition-related:
Warrants - Éclat Pharmaceuticals (a)	$	34,542	$	-	$	(13,925)	$	-	$	20,617
Earn-out payments - Éclat Pharmaceuticals (b)		70,112		(24,526)		44,882		-		90,468
Financing-related:
Royalty agreement - Deerfield (c)		6,837		(2,282)		-		3,307		7,862
Royalty agreement - Broadfin (d)		3,259		(1,089)		-		1,576		3,746
Total contingent consideration	$	114,750	$	(27,897)	$	30,957	$	4,883	$	122,693
Less: Current portion		(39,892)								(28,614)
Total long-term contingent consideration payable	$	74,858							$	94,079

Each of the above items is associated with related parties as further described in Footnote 18 – Related Parties.

(a)

As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.

(b)	As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC in March 2012, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat Pharmaceuticals products. These payments will continue in perpetuity.

(c)	As part of a February 2013 debt financing transaction conducted with Deerfield Management, a related party and current shareholder, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

(d)	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.

Schedule Of Fair Value Assumptions Of Warrant [Table Text Block]

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of December 31, 2015 and 2014:

	2015			2014
Weighted average exercise price per share	$	8.63		$	8.63
Expected term (years)		2.63			3.63
Expected volatility		64.54	%		54.80	%
Risk-free interest rate		0.93	%		1.25	%
Expected dividend yield		-			-